Abstract
The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is expressed on the surface of all human NK, NKT, CD8+ T, and subsets of γδ+ T cells. The significance of NKG2D function in tumor immunity has been well demonstrated in experimental animal models. However, the role of human NKG2D ligands in regulating tumor immunity and cancer prognosis had been controversial in the literature. In this review, we summarize the latest advancement, discuss the controversies, and present evidence that membrane-bound and soluble NKG2D ligands oppositely regulate tumor immunity. We also discuss new perspectives of targeting NKG2D ligands for cancer immunotherapy.
| Original language | English (US) |
|---|---|
| Article number | 00097 |
| Journal | Frontiers in immunology |
| Volume | 6 |
| Issue number | MAR |
| DOIs | |
| State | Published - 2015 |
Keywords
- Cancer
- NK cells
- NKG2D ligands
- T cells
- Tumor immunity
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Fingerprint Dive into the research topics of 'NKG2D ligands in tumor immunity: Two sides of a coin'. Together they form a unique fingerprint.
Cite this
Zhang, J., Basher, F., & Wu, J. D. (2015). NKG2D ligands in tumor immunity: Two sides of a coin. Frontiers in immunology, 6(MAR), [00097]. https://doi.org/10.3389/fimmu.2015.00097